Proposals by CapMan‘s Shareholders’ Nomination Board to the 2026 Annual General Meeting

CapMan’s Shareholders’ Nomination Board proposes re-election of six directors — Johan Bygge, Catarina Fagerholm, Joakim Frimodig, Mammu Kaario, Ari Kaperi and Eva Lindholm — and recommends voting on the slate as a whole at the Annual General Meeting planned for 25 March 2026. The board proposes modest increases in monthly cash fees (Chair EUR 5,650/month from EUR 5,450 in 2025; Deputy Chair EUR 4,500/month from EUR 4,350; Audit & Risk Chair EUR 4,500/month; ordinary members EUR 3,600/month) while keeping meeting fees unchanged (Chair EUR 800, members EUR 400). The Nomination Board also proposes amendments to its charter (timing, aggregated nomination rights, unanimity) and lists its four shareholder-appointed members; Joakim Frimodig is noted as non-independent due to recent employment and a board role in a >10% shareholder.

Analysis

Market structure: The Nomination Board’s re‑election slate and modest board fee increases preserve management continuity at CapMan (HE:CAPMAN) and protect existing strategy execution across €7.1bn AUM; incumbents and controlling shareholder Silvertärnan Ab (>10%) are clear winners, minority holders face slight governance dilution risk. Competitive dynamics among Nordic private-asset managers are unlikely to shift materially—market share remains tied to fund performance—but a small persistent governance discount (50–150bp valuation spread) could widen if investors price increased entrenchment. Supply/demand: liquidity in CapMan stock is thin relative to peers, so concentrated shareholdings increase illiquidity premium; expect muted flows into the name absent clear activist or take‑private catalysts. Cross-asset: negligible direct bond/commodity impact; FX and Finnish sovereign credit unaffected; small tick‑level repricing risk in equity options volatility for HE:CAPMAN around the AGM (25 Mar 2026).

Risk assessment: Tail risks include a proxy fight or regulatory challenge under Finnish corporate governance rules, which could impose a 10–30% hit to market cap if activism or minority lawsuits arise; operational risk is low given continuity. Time horizons: immediate (days) — small volatility around the release; short (weeks/months) — AGM outcome on 25 Mar 2026 is the primary catalyst; long (quarters) — potential valuation gap persists if charter changes entrench major holders. Hidden dependencies: nomination charter amendments around aggregation and unanimity can lock in board composition, reducing takeover arbitrage value and depressing takeover premium. Catalysts: shareholder votes, any stake increases by Silvertärnan, or an activist entrant (monitor 10–60 day window).

Key Decisions for Investors

• Reduce exposure to CapMan (HE:CAPMAN) by 2–4% of portfolio weight within 30 days ahead of the AGM (25 March 2026); implement an 8–12% stop‑loss and reassess post‑vote—close if board reappointment passes with >80% support and no charter empowerment changes.
• Initiate a pair trade: short HE:CAPMAN (size 1–2% NAV) and go long EQT AB (STO:EQT) equal notional for 3–6 months to capture relative governance/scale premium; rebalance if CAPMAN underperforms by >5% before AGM or if Silvertärnan stake rises above 15%.
• Purchase a hedged options position on HE:CAPMAN: buy 3‑month 10% OTM puts and sell 3‑month 3% OTM puts (put spread) sized to limit downside risk to 1–2% NAV; execute within 14 days to protect against AGM tail risk.
• For activist/engagement funds: conditionally accumulate up to 3% stake in HE:CAPMAN only if the nomination charter amendment text materially weakens minority nomination rights; file intent within 60 days and prepare to push for one independent director if stake >3%.
• Monitor three hard triggers over next 60 days and act: (A) Silvertärnan stake increases by >5 percentage points, (B) Nomination Charter final text grants aggregated holders exclusive nomination rights, (C) Pre‑AGM institutional voting signals show <70% support; if any occur, increase short size or hedges by 50%.